Lv1
30 积分 2026-05-21 加入
Protocol for a multinational, investigator-initiated, parallel-group, randomized, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)
10天前
已完结
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
10天前
已完结
IL-33 enhances responsiveness and mast cell mediator release in isolated human small airways
15天前
已完结
Epithelial alarmins TSLP, IL-33, and IL-25 in asthma pathogenesis: mechanistic roles and therapeutic implications
15天前
已完结
T2-low: what do we know?: Past, present, and future of biologic therapies in noneosinophilic asthma
16天前
已完结
A rational approach to compare and select biologic therapeutics in asthma
16天前
已完结
Airway hyperresponsiveness correlates with airway TSLP in asthma independent of eosinophilic inflammation
16天前
已完结
The level of asthma control in China from a national asthma control survey
17天前
已完结
支气管哮喘防治指南（2024年版）
17天前
已完结
Long term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo controlled extension study
19天前
已完结
皖公网安备34019202002308
